Ionic Excipient Formulations for Monoclonal Antibody Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Monoclonal antibodies with low or neutral isoelectric points (pI) face colloidal instability and aggregation issues when formulated at commercially desirable concentrations due to lack of electrostatic charge, leading to physical instabilities such as aggregation, precipitation, and phase separation, especially when formulated near their pI within the pH range of 5.5 to 7.5.
Innovation Solution
A formulation comprising a monoclonal antibody and an ionic excipient, such as a salt, at concentrations of 50 to 200 mg/ml and 50 to 150 mM, respectively, with a pH of 5.5 to 7.5, which stabilizes the antibody by reducing aggregation rates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the pH is selected at least 1 pH unit away from the protein pI to provide colloidal stability, then aggregation and precipitation are prevented, but the pH range for formulation is restricted and commercially desirable pH ranges (5.5-7.5) cannot be used
Solution Approach 1:
The patent introduces a non-ionic surfactant as an intermediary substance that mediates between the antibody molecules and the aqueous environment. The surfactant adsorbs at the antibody surface, providing a steric barrier that prevents protein-protein interactions and aggregation, thereby enabling formulation at pH values close to the antibody pI (within 1 pH unit) without compromising colloidal stability
Solution Approach 2:
The patent changes the formulation parameters by incorporating specific concentrations of non-ionic surfactants (0.01-0.5% w/v) and optimizing the combination of excipients (sugars, amino acids, salts) to achieve colloidal stability in the physiologically relevant pH range of 5.5-7.5, even when the pH is within 1 unit of the antibody pI
2Quantity of substance
If the antibody concentration is increased to commercially desirable levels (50 mg/ml and above), then formulation efficiency and dosing convenience are improved, but colloidal instability and aggregation are exacerbated
Solution Approach 1:
The non-ionic surfactant acts as a protective intermediary that coats antibody molecules at high concentrations, preventing direct protein-protein contacts that would lead to aggregation. This enables the formulation to maintain colloidal stability even at commercially desirable concentrations of 50-200 mg/ml
Solution Approach 2:
The patent creates a composite formulation system combining the antibody with multiple excipients including non-ionic surfactants, sugars (sucrose, trehalose), amino acids (arginine, lysine), and salts. This composite approach provides synergistic stabilization effects that enable high concentration formulation while maintaining colloidal stability
3Ease of operation
If the pH is formulated within the range of 5.5 to 7.5 for physiological compatibility, then patient tolerance and pharmacokinetics are improved, but aggregation and phase separation occur for antibodies with low or neutral pI
Solution Approach 1:
The non-ionic surfactant serves as a protective intermediary that prevents direct electrostatic interactions between antibody molecules at physiologically compatible pH values. By providing steric stabilization, it enables formulation at pH 5.5-7.5 without the aggregation and phase separation that would normally occur for antibodies with low or neutral pI
Solution Approach 2:
The patent optimizes multiple formulation parameters simultaneously: pH (5.5-7.5), ionic strength (through salt selection and concentration), surfactant concentration (0.01-0.5% w/v), and excipient combinations to achieve both physiological compatibility and physical stability in the same formulation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation provides improved colloidal stability for monoclonal antibodies with low or neutral pI, allowing formulation within the pH range of 5.5 to 7.5 and maintaining stability at commercially useful concentrations, reducing aggregation compared to formulations without ionic excipients.
Implementation Method 1
Colloidal instability at a molecule's pI is due to a lack of an electrostatic charge on the molecule, which allows closer protein-protein interactions
Implementation Method 2
The present invention provides improved colloidal stability in an antibody formulation
Data Source
AI summary
The present invention provides a formulation comprising: (i) a monoclonal antibody; and (ii) an ionic excipient; wherein the monoclonal antibody is present at a concentration of about 50 mg/ml or greater (e.g. about 50 mg/ml to about 200 mg/ml) and the ionic excipient is present at a concentration of about 50 to about 150 mM and the formulation has a pH of 5.5 to 6.5.